Pour garantir une navigation aussi fonctionnelle que possible, notre site utilise des cookies, y compris des «cookies tiers» et des «cookies de profilage» conçus pour ajuster le contenu en ligne aux préférences exprimées par l’utilisateur lorsqu’il surfe sur Internet. Si vous souhaitez obtenir plus d’information ou refusez votre consentement à certains ou à tous les cookies, cliquez ici. En débutant votre navigation sur notre site Internet, vous consentez de fait à l’utilisation de tous les cookies.

News

Menarini Group announced its 2019 results
Il Gruppo Menarini (“Menarini”)  e Stemline Therapeutics  Inc. (“Stemline”), azienda biofarmaceutica americana focalizzata sullo sviluppo e la  commercializzazione di terapie oncologiche innovative, (NASDAQ: STML) annunc...
Toutes les news »
10 juin 2020

Menarini Group Completes a Solid Year of Operating Performance



  • Turnover reaches €3,793 million, with an increase of 3.2% compared to 2018 and EBITDA of €492 million thanks to continued strong performance of its most important products.
  • €150 million investment into new plant in Italy significantly increasing oral blister capacity in line with increased demand.
  • Completion of Stemline acquisition, a US based biopharmaceutical company, marks Menarini Group’s pivotal entry into the world’s largest pharma market.

FLORENCE – June 10, 2020 – Menarini Group, a privately held Italian pharmaceutical and diagnostics company, announced its 2019 results.

Turnover reaches nearly € 3.8 billion (€3,793 million), with an increase of 3.2% compared to2018, and EBITDA of €492 million. Growth was mainly driven by international markets despite the patent expiration of Adenuric (febuxostat), a drug for hyperuricemia. The year that ended was obviously not affected by the COVID-19 crisis and saw Menarini increase its presence abroad with international turnover reaching 77% of the global total.

Elcin Barker Ergun, CEO of Menarini Group, commented, “2019 was another year of solid operating performance for Menarini with continued top-line growth despite a major patent loss. In line with continued strong growth of our most important products, we have just announced a major new manufacturing site investment in Florence to significantly increase our oral blisters capacity. Looking ahead, we remain focused on our strategic priorities in primary and specialty care to serve millions of patients around the world. The acquisition of Stemline, a New York-based US biopharmaceutical company, which we have just completed is a key move in line with our strategy providing us an excellent foundation to tap into the world’s largest pharmaceutical market and greatly enhancing our innovation power.”



Diagnostic

Technologie avancée.

LIRE LA SUITE »

Menarini dans le monde

Le Groupe Menarini possède des bureaux situées dans la plupart du monde.

LIRE LA SUITE »

Nos valeurs

 

10 valeurs fondamentales ont influencé les progrès de notre groupe.

LIRE LA SUITE »

Postes vacantes

Nous sommes à la recherche de personnes de talent. Découvrez les possibilités!

LIRE LA SUITE »